Charles Okechukwu Esimone
Nnamdi Azikiwe University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Charles Okechukwu Esimone.
Annals of Clinical Microbiology and Antimicrobials | 2012
Ifeanyichukwu R Iroha; Charles Okechukwu Esimone; Sandra Neumann; Lennart Marlinghaus; Miriam Korte; Florian Szabados; Sören Gatermann; Martin Kaase
We studied the presence of extended spectrum beta lactamases (ESBLs) in 44 clinical isolates of Escherichia coli collected from out-patients in two university teaching hospitals in South-Eastern Nigeria. Species identification was performed by standard microbiology methods and re-confirmed by MALDI-TOF technology. Phenotypic characterization of ESBL enzymes was done by double disc synergy test and presence of ESBL genes was determined by specific PCR followed by sequencing. Transfer of plasmid DNA was carried out by transformation using E. coli DH5 as recipient strain. Phenotypic characterization identified all isolates to be ESBL positive. 77% of strains were from urine, 13.6% from vaginal swabs and 9.0% from wound swabs. 63.6% were from female patients, 68% were from outpatients and 95.5% from patients younger than 30 years. All ESBL producers were positive in a PCR for blaCTX-M-1 cluster, in exemplary strains blaCTX-M-15 was found by sequencing. In all strains ISEcp1 was found upstream and ORF477 downstream of blaCTX-M. PCR for blaTEM and blaOXA-1 was positive in 93.1% of strains, whereas blaSHV was not detected, aac(6′)-Ib-cr was found in 97.7% of strains. RAPD analysis revealed seven different clonal groups named A through G with the majority of the strains (65.9%) belonging to clone A. Transfer of an ESBL plasmid with co-resistance to gentamicin, kanamycin, tobramycin, doxycycline and trimethropim-sulfamethoxazole was successful in 19 (43.2%) strains. This study showed a high rate of CTX-M-1 cluster - ESBLs in South-Eastern Nigeria and further confirms the worldwide spread of CTX-M ESBL in clinical isolates.
Malaria Journal | 2014
Charles Ezenduka; Brian O Ogbonna; Obinna Ikechukwu Ekwunife; Mathew Jegbefume Okonta; Charles Okechukwu Esimone
BackgroundMalaria treatment policy recommends regular monitoring of drug utilization to generate information for ensuring effective use of anti-malarial drugs in Nigeria. This information is currently limited in the retail sector which constitutes a major source of malaria treatment in Nigeria, but are characterized by significant inappropriate use of drugs. This study analyzed the use pattern of anti-malarial drugs in medicine outlets to assess the current state of compliance to policy on the use of artemisinin-based combination therapy (ACT).MethodsA prospective cross-sectional survey of randomly selected medicine outlets in Enugu urban, southeast Nigeria, was conducted between May and August 2013, to determine the types, range, prices, and use pattern of anti-malarial drugs dispensed from pharmacies and patent medicine vendors (PMVs). Data were collected and analyzed for anti-malarial drugs dispensed for self-medication to patients, treatment by retail outlets and prescription from hospitals.ResultsA total of 1,321 anti-malarial drugs prescriptions were analyzed. ACT accounted for 72.7%, while monotherapy was 27.3%. Affordable Medicines Facility-malaria (AMFm) drugs contributed 33.9% (326/961) of ACT. Artemether-lumefantrine (AL), 668 (50.6%) was the most used anti-malarial drug, followed by monotherapy sulphadoxine-pyrimethamine (SP), 248 (18.8%). Median cost of ACT at
Journal of Immunotoxicology | 2011
Chukwuemeka S. Nworu; Peter A. Akah; Festus B.C. Okoye; Donatien Kamdem Toukam; Judith Udeh; Charles Okechukwu Esimone
2.91 (
African Journal of Biotechnology | 2009
Dominic O. Abonyi; M.U Abonyi; Charles Okechukwu Esimone; Ec Ibezim
0.65-7.42) per dose, is about three times the median cost of monotherapy,
Immunopharmacology and Immunotoxicology | 2012
Chukwuemeka S. Nworu; Peter A. Akah; Festus B. C. Okoye; Charles Okechukwu Esimone
0.97 (
Planta Medica | 2013
Daowan Lai; Damian C. Odimegwu; Charles Okechukwu Esimone; Thomas Grunwald; Peter Proksch
0.19-13.55). Total cost of medication (including co-medications) with ACT averaged
Asian pacific Journal of Tropical Biomedicine | 2012
Mumuni A. Momoh; Charles Okechukwu Esimone
3.64 (95% CI;
Natural Product Research | 2011
Festus B. C. Okoye; Patience O. Osadebe; Chukwuemeka S. Nworu; N.N. Okoye; Edwin Ogechukwu Omeje; Charles Okechukwu Esimone
3.53-3.75) per prescription, about twice the mean cost of treatment with monotherapy,
Immunological Investigations | 2010
Chukwuemeka S. Nworu; Peter A. Akah; Festus B. C. Okoye; Peter Proksch; Charles Okechukwu Esimone
1.83 (95% CI;
Journal of Pharmaceutical Policy and Practice | 2014
Charles Ezenduka; Mathew Jegbefume Okonta; Charles Okechukwu Esimone
1.57-2.1). Highest proportion 46.5% (614), of the anti-malarial drugs was dispensed to patients for self-treatment. Treatment by retail outlets accounted for 35.8% while 17.7% of the drugs were dispensed from hospital prescriptions. Self-medication, 82%, accounted for the highest source of monotherapy and a majority of prescriptions, 85.6%, was adults.ConclusionFindings suggest vastly improved use of ACT in the retail sector after eight years of policy change, with significant contributions from AMFm drugs. However the use of monotherapy, particularly through self-medication remains significant with increasing risk of undermining treatment policy, suggesting additional measures to directly target consumers and providers in the sector for improved use of anti-malarial drugs in Nigeria.